Literature DB >> 18839140

Once is not enough: clinical trials in sepsis.

Daniel A Sweeney, Robert L Danner, Peter Q Eichacker, Charles Natanson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18839140     DOI： 10.1007/s00134-008-1274-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


× No keyword cloud information.
  46 in total

1.  Anti-endotoxin monoclonal antibodies.

Authors:  H S Warren; R L Danner; R S Munford
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

2.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

3.  Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group.

Authors: 
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

4.  Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

Authors:  R V McCloskey; R C Straube; C Sanders; S M Smith; C R Smith
Journal:  Ann Intern Med       Date:  1994-07-01       Impact factor: 25.391

Review 5.  Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review.

Authors:  Julie Pildal; Peter C Gøtzsche
Journal:  Clin Infect Dis       Date:  2004-06-01       Impact factor: 9.079

6.  Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial.

Authors:  T Calandra; M P Glauser; J Schellekens; J Verhoef
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

7.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.

Authors:  R Phillip Dellinger; Jean M Carlet; Henry Masur; Herwig Gerlach; Thierry Calandra; Jonathan Cohen; Juan Gea-Banacloche; Didier Keh; John C Marshall; Margaret M Parker; Graham Ramsay; Janice L Zimmerman; Jean-Louis Vincent; M M Levy
Journal:  Intensive Care Med       Date:  2004-03-03       Impact factor: 17.440

8.  Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.

Authors:  Renda Soylemez Wiener; Daniel C Wiener; Robin J Larson
Journal:  JAMA       Date:  2008-08-27       Impact factor: 56.272

9.  Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock.

Authors:  Simon Finfer; V Marco Ranieri; B Taylor Thompson; Philip S Barie; Jean-François Dhainaut; Ivor S Douglas; Bengt Gårdlund; John C Marshall; Andrew Rhodes
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

10.  Drotrecogin alfa (activated): real-life use and outcomes for the UK.

Authors:  Kathryn M Rowan; Catherine A Welch; Emma North; David A Harrison
Journal:  Crit Care       Date:  2008-04-22       Impact factor: 9.097
View more
  23 in total

Review 1.  Risk factors for sepsis after percutaneous renal stone surgery.

Authors:  Evgeniy I Kreydin; Brian H Eisner
Journal:  Nat Rev Urol       Date:  2013-09-03       Impact factor: 14.432

Review 2.  The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

Authors:  Lara Marks
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

3.  Prolonging resuscitation and postponing the death of activated protein C or is it?

Authors:  Kaggere Shivalingaiah Paramesh; Jim Zwaal
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

4.  Targeting F box protein Fbxo3 to control cytokine-driven inflammation.

Authors:  Rama K Mallampalli; Tiffany A Coon; Jennifer R Glasser; Claire Wang; Sarah R Dunn; Nathaniel M Weathington; Jing Zhao; Chunbin Zou; Yutong Zhao; Bill B Chen
Journal:  J Immunol       Date:  2013-10-11       Impact factor: 5.422

5.  Editors' comments on a new trial of activated protein C for persistent septic shock.

Authors:  Jordi Mancebo; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

6.  Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors.

Authors:  Lena Heinbockel; Susana Sánchez-Gómez; Guillermo Martinez de Tejada; Sabine Dömming; Julius Brandenburg; Yani Kaconis; Mathias Hornef; Aline Dupont; Sebastian Marwitz; Torsten Goldmann; Martin Ernst; Thomas Gutsmann; Tobias Schürholz; Klaus Brandenburg
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

Review 7.  Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.

Authors:  Derek S Wheeler; Basilia Zingarelli; William J Wheeler; Hector R Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2009-06

Review 8.  Systems engineering medicine: engineering the inflammation response to infectious and traumatic challenges.

Authors:  Robert S Parker; Gilles Clermont
Journal:  J R Soc Interface       Date:  2010-02-10       Impact factor: 4.118

9.  The impact of cardiac dysfunction on acute respiratory distress syndrome and mortality in mechanically ventilated patients with severe sepsis and septic shock: an observational study.

Authors:  Brian M Fuller; Nicholas M Mohr; Thomas J Graetz; Isaac P Lynch; Matthew Dettmer; Kevin Cullison; Talia Coney; Swetha Gogineni; Robert Gregory
Journal:  J Crit Care       Date:  2014-08-07       Impact factor: 3.425

10.  Statin research in critical illness: hampered by poor trial design?

Authors:  Marius Terblanche; Neill K J Adhikari
Journal:  Crit Care       Date:  2009-12-11       Impact factor: 9.097
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.